# Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

> **NCT07531095** · PHASE1 · RECRUITING · sponsor: **Amgen** · enrollment: 160 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** ZL-1310
- **DRUG:** Tarlatamab
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT07531095
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2028-05-21
- **Final completion:** 2031-05-21
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07531095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07531095, "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT07531095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*